Drug Development Consulting Holding ApS - CVR: 42285722

2022, DKK

16.06.2023

Bruttoresultat

-58.000

Primær drift

-58.000

Årets resultat

-11.874'

Aktiver

72.021'

Kortfristede aktiver

190'

Egenkapital

71.988'

Afkastningsgrad

-0 %

Soliditetsgrad

100 %

Likviditetsgrad

+500%

Resultat

16.06.2023

Årsrapport	2022 16.06.2023	2021 31.05.2022
Nettoomsætning
Bruttoresultat	-58.000	40.000
Resultat af primær drift	-58.000	40.000
Indtægter af kapitalandele (tilknyttede og associerede)	-11.831.000	-15.752.000
Finansielle indtægter	17.000	0
Finansieringsomkostninger	0	0
Andre finansielle omkostninger	0	0
Resultat før skat	-11.872.000	0
Resultat	-11.874.000	-15.712.000
Forslag til udbytte	0	0

Aktiver

16.06.2023

Årsrapport	2022 16.06.2023	2021 31.05.2022
Kortfristede varebeholdninger	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	7.000	0
Likvider	183.000	0
Kortfristede aktiver	190.000	0
Immaterielle aktiver og goodwill	0	0
Finansielle anlægsaktiver	71.831.000	70.809.000
Materielle aktiver	0	0
Langfristede aktiver	71.831.000	70.809.000
Aktiver	72.021.000	70.809.000

Aktiver

16.06.2023

Passiver

16.06.2023

Årsrapport	2022 16.06.2023	2021 31.05.2022
Forslag til udbytte	0	0
Egenkapital	71.988.000	70.809.000
Hensatte forpligtelser	0	0
Langfristet gæld til banker	0	0
Anden langfristet gæld	0	0
Leverandører af varer og tjenesteydelser	0	0
Kortfristede forpligtelser	33.000	0
Gældsforpligtelser	0	0
Forpligtelser	0	0
Passiver	72.021.000	70.809.000

Passiver

16.06.2023

Nøgletal

16.06.2023

Årsrapport	2022 16.06.2023	2021 31.05.2022
Afkastningsgrad	-0,1 %	0,1 %
Dækningsgrad	Na.	Na.
Resultatgrad	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.
Egenkapitals-forretning	-16,5 %	-22,2 %
Payout-ratio	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.
Soliditestgrad	100,0 %	100,0 %
Likviditetsgrad	575,8 %	Na.

Resultat

16.06.2023

Gæld

16.06.2023

Årsrapport

16.06.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 16.06.2023)

Beretning

16.06.2023

Dato for ledelsens godkendelse af årsrapporten:2023-05-24

Ledelsespåtegning:Statement by the Board of Directors and the Executive Board

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Drug Development Consulting Holding ApS for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business reviewDrug Development Consulting Holding ApS was established on 7 April 2021 and on 17 May 2021 Gilde Healthcare, a private equity company with headquarter in the Netherlands, acquired the KLIFO A/S (the KLIFO Group) through subsidiary Drug Development Consulting BidCo ApS. Drug Development Consulting Holding ApS is a shareholder company with no operational activities. KLIFO Group structureKLIFO Group is a drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects. KLIFO offers cross functional consulting and operational solutions spanning all areas of strategic advises, regulatory affairs, CMC development, clinical research, pharmacovigilance, clinical trial supply and quality assurance. Over the past decade, KLIFO has grown to become an established and integrated drug development consultancy providing end to end expert capabilities, enabling our partners to maximize opportunity, mitigate risks, drive innovation and achieve efficient project advancement. The year of 2022 has been a return to “normal business” after COVID-19. KLIFO has continued to strengthen our European market position by increasing revenue in Germany, Switzerland, Sweden and Denmark. In Germany a new General Manager has been engaged and the organisation has been adjusted to meet the needs in the market. For KLIFO in general, the main change compared to before COVID has been the dynamics in the job market where the demand for talent has been higher than ever. This has also impacted staff turnover in KLIFO and been the main reason for a lower growth rate than earlier years. Looking ahead, KLIFO will continue investing in growth and in strengthening the organisation.